Desai A, Zator ZA, de Silva P, et al. - Since awareness of outcomes of older patients treated with biologics is becoming more important in increasingly aging populations, researchers conducted this retrospective single-center study to analyze the safety and durability of anti-tumor necrosis factor (TNF) therapy in this subgroup. The study sample consisted of cases involving all IBD patients who started anti-TNF treatment at age > 60 years. From medical record review, they identified cases of Crohn's disease (CD) and ulcerative colitis (UC). To calculate the probability of remaining on anti-TNF therapy, Kaplan–Meier survival estimates were used. A total of 54 IBD patients who started anti-TNF therapy over the age of 60 years (mean 73, range 61–97 years) were identified. At the time of initiation of anti-TNF treatment, the IBD population over 60 years of age is at higher risk of discontinuation of therapy. They may also be particularly vulnerable to complications involving infection that require hospitalization, highlighting the need for careful monitoring during therapy.